出生日期
1960.04.12
申请专业
外科学
职称
教授
邮箱:nashan@ustc.edu.cn

主要行政或学术兼职
器官移植中心主任

主要学习、工作、出国经历
1987 –2000: 历任外科学讲师、副教授，汉诺威医学院
2000 –2004: 外科学教授， 汉诺威医学院
2004 –2007: 教授，加拿大Dalhousie大学
2007 –2016: 普通外科、血管外科、器官移植外科主任，汉堡大学

主要研究方向及特色
肝胆胰外科及肝移植外科临床及基础研究：
1.移植排斥免疫反应信号通路
2.移植术后病人个体化免疫抑制策略
3.肝移植和肝胆胰外科的临床研究

代表性成果简介

此前担任德国汉堡大学附属医院肝胆胰外科、肝肾胰移植中心主任以及德国移植协会主席，现为美国外科学院院士、加拿大皇家外科学院院士，在包括NEJM、Lancet等在内的国际权威杂志上发表论文百余篇，促进了相关学科的发展；代表论文如：
1.AvoidAll-TouchbyHybridALPPStoAchieveOncologicalEfficacy.Annalsofsurgery.10.1097/SLA.0845
2.Kidneytransplantationinsmallchildren:Donorselectionandtechnicalconsideration.Transplantation.2002;73:409-16.
3.Preoperativevolumecalculationofthehepaticvenousdrainingareaswithmulti-detectorrowCTinadultlivingdonorlivertransplantation:impactonsurgicalprocedure.EurRadiol2006
4.ComparingSurgicalComplicationsofDonorsandRecipientsinRetroperitoneoscopicversusMini-IncisionDonorNephrectomy:ASingle-CenterExp

发表论文名称（近5年）
Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant. Transplantation. 2012 Jun 15;93(11):1075-85.Nashan B, Gaston R, Emery V, S?emann MD, Mueller NJ, Couzi L, Dantal J, Shihab F, Mulgaonkar S, Seun Kim Y, Brennan DC。
Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. Rev Med Virol. 2013 Mar;23(2):97-125.Brennan DC, Aguado JM, Potena L, Jardine AG, Legendre C, S?emann MD, Mueller NJ, Merville P, Emery V, Nashan B
Lack of association between CTLA-4 and PDCD1 polymorphisms and acute rejection in German liver transplant recipients. Hum Immunol. 2013 Apr 27.Thude H, Schipler AD, Treszl A, Peine S, Koch M, Sterneck M, Nashan B
Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with. rituximab, splenectomy, and bortezomib. Transpl Int. 2013 Apr 26.Koch M, Gr?ser C, Lehnhardt A, Pollok JM, Kr?ger N, Verboom M, Thaiss F, Eiermann T, Nashan B
Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients. Clin Transplant. 2013 Jul;27 Suppl 25:16-29.Nashan B
The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy. CLIN TRANSPLANT, 28(6), 635-48. 10.1111/ctr.12357。Klintmalm GB, Saab S, Hong JC, Nashan B
Lack of association between CD40 polymorphisms and acute rejection in German liver transplant recipients. HUM IMMUNOL, 75(11), 1123-7.Thude H, Kramer K, Koch M, Peine S, Sterneck M, Nashan B
mTOR inhibitors and their role in modern concepts of immunosuppression. WORLD J SURG, 38(12), 3199-201.Nashan B
Avoid All-Touch by Hybrid ALPPS to Achieve Oncological Efficacy. Annals of surgery.Li J, Kantas A, Ittrich H, Koops A, Achilles E., Fischer L, Nashan B
Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. TRIALS, 16(1), 118.Nashan B, Schemmer P, Braun F, Dworak M, Wimmer P, Schlitt H

本人目前正在承担的科研项目(仅限于主要负责人)

项目名称、来源、经费指标卡号
总经费(万元)
起止日期

ACTICCA Trial：Adjuvant chemotherapy with gemcitabine and cisplatine compareid to observation after curative intent resection of cholangiocarcinoma –A randomized, controlled, multidisciplinary AIO/DGAV/DGVS phase III trial, Sponsor: Deutsche Krebshilfe


2013 –ongoing

CRAD001H2307: A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living donor liver transplants.

2013 –ongoing

Elevate, CRAD001A2429: A 24-month, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calcineurin inhibitor to everolimus conversion.

2012 –ongoing